Adam Maeder
Stock Analyst at Piper Sandler
(4.07)
# 596
Out of 4,667 analysts
94
Total ratings
57.14%
Success rate
10.79%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $12 → $11 | $9.03 | +16.28% | 6 | Nov 13, 2024 | |
| NVRO Nevro | Maintains: Underweight | $7 → $6 | $4.23 | +41.84% | 15 | Nov 12, 2024 | |
| INSP Inspire Medical Systems | Reiterates: Overweight | $255 → $260 | $184.77 | +40.72% | 13 | Nov 5, 2024 | |
| NARI Inari Medical | Maintains: Neutral | $50 → $52 | $49.00 | +6.12% | 6 | Oct 29, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $73 → $70 | $69.54 | +0.66% | 12 | Oct 25, 2024 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $495 → $538 | $541.82 | -0.71% | 17 | Oct 18, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $131 → $133 | $115.93 | +14.72% | 2 | Oct 17, 2024 | |
| NSPR InspireMD | Reiterates: Overweight | $4.5 | $2.64 | +70.45% | 3 | Sep 17, 2024 | |
| M Macy's | Maintains: Hold | $20 → $21 | $14.56 | +44.23% | 2 | May 22, 2024 | |
| STIM Neuronetics | Reiterates: Overweight | $7 → $8 | $0.80 | +896.88% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $8.21 | +143.61% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $15.56 | +92.80% | 2 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.03 | +146.31% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $7.86 | +129.01% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $50.05 | +97.80% | 3 | May 5, 2022 |
Vicarious Surgical
Nov 13, 2024
Maintains: Neutral
Price Target: $12 → $11
Current: $9.03
Upside: +16.28%
Nevro
Nov 12, 2024
Maintains: Underweight
Price Target: $7 → $6
Current: $4.23
Upside: +41.84%
Inspire Medical Systems
Nov 5, 2024
Reiterates: Overweight
Price Target: $255 → $260
Current: $184.77
Upside: +40.72%
Inari Medical
Oct 29, 2024
Maintains: Neutral
Price Target: $50 → $52
Current: $49.00
Upside: +6.12%
Edwards Lifesciences
Oct 25, 2024
Maintains: Neutral
Price Target: $73 → $70
Current: $69.54
Upside: +0.66%
Intuitive Surgical
Oct 18, 2024
Reiterates: Overweight
Price Target: $495 → $538
Current: $541.82
Upside: -0.71%
Abbott Laboratories
Oct 17, 2024
Maintains: Overweight
Price Target: $131 → $133
Current: $115.93
Upside: +14.72%
InspireMD
Sep 17, 2024
Reiterates: Overweight
Price Target: $4.5
Current: $2.64
Upside: +70.45%
Macy's
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $14.56
Upside: +44.23%
Neuronetics
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $0.80
Upside: +896.88%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $8.21
Upside: +143.61%
May 9, 2023
Maintains: Overweight
Price Target: $25 → $30
Current: $15.56
Upside: +92.80%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.03
Upside: +146.31%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $7.86
Upside: +129.01%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $50.05
Upside: +97.80%